PolyPid's $4.3M FDA Windfall Speeds Path for Groundbreaking Anti-Infection Drug

PETACH TIKVA, Israel – March 17, 2026 – PolyPid Ltd. (Nasdaq: PYPD) received a significant financial and strategic boost today after the U.S. Food and Drug Administration (FDA) granted a full waiver of the Prescription Drug User Fee Act (PDUFA) fee for its upcoming New Drug Application (NDA). The waiver, valued at approximately $4.3 million, removes a major financial hurdle for the Israeli biopharmaceutical company as it prepares to seek approval for D-PLEX₁₀₀, its lead product candidate for preventing surgical site infections.

This development allows PolyPid to redirect substantial capital towards critical commercialization activities, a pivotal move as the company stands on the cusp of transitioning from a clinical-stage entity to a commercial enterprise. The company confirmed it remains on track to begin its rolling NDA submission to the FDA before the end of this month, a timeline bolstered by positive feedback received from the agency in December 2025.

A Critical Financial Lifeline

The PDUFA fee waiver is more than just a regulatory footnote; it represents a vital injection of financial flexibility for a small biopharmaceutical firm. PDUFA fees, which reached over $4.6 million per application in fiscal year 2026, are a substantial upfront cost required to fund the FDA's review process. For a company like PolyPid, which reported cash reserves of $12.9 million at the end of 2025 against a net loss of $34.2 million for the year, the waiver is a material event. The saved $4.3 million represents roughly a third of its cash on hand, preserving precious capital that can now be deployed for market preparation and partnership building.

The waiver was granted under the FDA's small business provision, designed to support emerging companies submitting their first drug application. This provision acknowledges the financial pressures on innovative firms that have yet to generate product revenue. By alleviating this burden, the FDA enables PolyPid to focus its resources on what comes next: preparing the U.S. market for a potentially transformative new therapy.

"We are pleased to receive this PDUFA fee waiver days before our planned NDA submission," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid, in a statement. "Following our landmark Phase 3 SHIELD II results and productive engagement with the FDA on our rolling NDA review approach, we continue to make significant progress toward bringing D-PLEX₁₀₀ to market."

The Clinical Promise of D-PLEX₁₀₀

The excitement surrounding PolyPid is anchored in the strong clinical performance of D-PLEX₁₀₀. The product is designed to combat surgical site infections (SSIs), a persistent and costly complication of surgery, particularly in complex procedures like abdominal colorectal operations. SSIs lead to patient suffering, prolonged hospital stays, and a significant financial burden on the healthcare system.

D-PLEX₁₀₀ is not just another antibiotic. It utilizes PolyPid's proprietary Kynatrix delivery technology, a polymer-lipid matrix that encases the broad-spectrum antibiotic doxycycline. Administered directly into the surgical site before closure, it is engineered to provide a controlled, continuous release of the drug locally for 30 days. This approach is designed to maintain a high concentration of the antibiotic where it's needed most, protecting the patient throughout the critical post-operative healing period.

The efficacy of this novel approach was demonstrated in the pivotal Phase 3 SHIELD II trial. The study, which focused on patients undergoing abdominal colorectal surgery with large incisions, showed that D-PLEX₁₀₀ achieved a statistically significant 60% relative risk reduction in SSIs compared to the standard of care. The trial successfully met its primary and all key secondary endpoints, a resounding success that underpins the company's confidence and the FDA's engagement.

Navigating the Path to Market

The journey of D-PLEX₁₀₀ has been accelerated by a series of favorable regulatory designations. The FDA has granted it Breakthrough Therapy Designation, a status reserved for drugs that may demonstrate substantial improvement over available therapies for serious conditions. This designation, along with Fast Track and Qualified Infectious Disease Product (QIDP) status, provides for more frequent communication with the FDA and a potentially expedited review process.

The agency's agreement to a rolling NDA review further streamlines this path. This process allows PolyPid to submit completed sections of its application for review as they are finished, rather than waiting for the entire package to be compiled. This can shorten the overall time from submission to a final decision, a crucial advantage in the fast-moving pharmaceutical landscape.

With the clinical data package deemed sufficient by the FDA during pre-NDA discussions, the company is now executing the final steps before submission. The combination of strong data, multiple facilitating regulatory designations, and now financial relief from the PDUFA fee creates a powerful tailwind as D-PLEX₁₀₀ enters the final leg of its regulatory race.

As the company prepares for a potential launch, its focus shifts to commercial strategy. Akselbrad noted that PolyPid is in "advanced stages of commercial partnership discussions for the U.S. market," signaling a strategy to leverage the expertise and infrastructure of a larger partner to maximize D-PLEX₁₀₀'s market penetration. For PolyPid, 2026 is shaping up to be what its CEO calls a "transformative year," as the company works to deliver on the promise of its science and bring a new weapon in the fight against surgical infections to patients and surgeons.